Clinical Trials Browser

Terminated × Doxorubicin × Plasma cell × Clear all

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01177683 2023-10-06

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Phase 1/2 Terminated

32 enrolled 18 charts

Plasma cell

Multiple Myeloma

NCT02128230 2021-06-22

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Phase 2 Terminated

20 enrolled 7 charts

Plasma cell

Multiple Myeloma

NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Phase 2 Terminated

442 enrolled 17 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT01548573 2017-06-14

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Phase 2 Terminated

19 enrolled 7 charts

Plasma cell

Amyloidosis, Endocrine System Diseases, Multiple Myeloma, Paraproteinemias, Polyneuropathies

NCT00215943 2014-04-17

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

Phase 3 Terminated

90 enrolled 10 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT00441168 2014-03-21

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Phase 2 Terminated

30 enrolled 14 charts

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Clinical Trials

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma